![]() ![]() Through its population-based approach and data-mining techniques, deCODE seeks to turn raw genomics data into products and services for the healthcare industry. Last year, the two companies announced the identification of a narrow chromosomal region carrying a gene that contributes to osteoarthritis.ĭeCODE genetics (is conducting research into the inherited causes of common diseases. ![]() In March 2000, Roche announced that deCODE scientists had mapped a gene linked to stroke. Jonathan Knowles, Head of Global Research at Roche added, “We are very impressed by the rapid progress made by deCODE genetics towards identifying genes that play important roles in the molecular pathology of common diseases.” This work underscores the feasibility and power of studying common complex diseases using Iceland’s unique resources.” Kari Stefansson, CEO of deCODE genetics noted that, “We have made significant progress towards finding a novel gene that, depending on the presence of certain molecular variations, contributes to the common form of Alzheimer’s disease. Although progress has been made during the past decade in the diagnosis and treatment of Alzheimer’s disease, there is still no cure. Due to the continuing rise in life expectancy, the disease and its associated burden of suffering among individuals and their families and its costs to society are becoming ever more significant public health problems. deCODE genetics has received an undisclosed milestone payment from Roche for this accomplishment.Īlzheimer’s disease, the most common cause of dementia in the elderly, affects about 5% of people over the age of 65. Roche plans to initiate discovery and development programs for new diagnostics and therapeutics building on this genetic information. This finding underscores the role of genetics in the pathogenesis of this devastating illness, and represents a critical milestone on the way to identifying a gene and its disease-linked variants. The location of the gene linked to Alzheimer’s disease within a narrow chromosomal region was achieved through a study focusing on Alzheimer’s disease as a public health problem involving 1,100 participating Icelandic patients and their unaffected relatives. „A good biomarker for OA, such as CRTAC1 could dramatically increase the probability of the development of good medicine for the disease that the world is waiting for,“ says Kari Stefansson CEO of deCODE genetics.Reykjavik, ICELAND, and Basel, SWITZERLAND, AugdeCODE genetics (Nasdaq/Easdaq: DCGN) and F.Hoffmann-La Roche announced today that scientists at deCODE have successfully mapped a novel gene that contributes to the occurrence of the common form of Alzheimer’s disease (often referred to as late-onset Alzheimer’s). “There is still a long way to go with validation in other population as the most important next step.” “These results are very encouraging and may provide the first steps towards a good biomarker of osteoarthritis to use in the clinic,” says Unnur Styrkarsdottir author on the paper. CRTAC1 outperforms previously reported biomarkers for osteoarthritis, and is an independent predictor of disease. People with higher levels of CRTAC1 in plasma are at increased risk, and have a more severe disease. ![]() Currently there are no drugs specific for osteoarthritis treatment, mostly because of a lack of a good biomarker that could help diagnose patients, select patients into clinical trials and/or monitor disease progression. ![]() Osteoarthritis affects over 300 million people worldwide. The new promising biomarker is the Cartilage Acidic protein 1 (CRTAC1) which not only associates with osteoarthritis diagnosis of hands, hips, and knees, but also predicts progression to joint replacements. Using SOMAscan platform in a non-hypothesis driven scan of 4,792 plasma proteins in 39,155 Icelanders, higher levels of CRTAC1 in plasma correlate with osteoarthritis severity and predict progression to joint replacement. In a study published in the medical journal, Arthritis & Rheumatology, scientists at deCODE genetics, a subsidiary of Amgen, introduce a new biomarker for osteoarthritis. Kari Stefansson and Unnur Styrkarsdpttir. Scientists at deCODE genetics have found a new biomarker for osteoarthritis, that outperforms previously reported biomarkers and is an independent predictor of disease. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |